In This Issue
Cancer Discov February 1 2017 7 (2) 115-117; DOI:10.1158/2159-8290.CD-ITI7-2
The hematologic malignancy blastic plasmacytoid dendritic cell neoplasm is characterized by sensitivity to BCL2 inhibition with venetoclax in vitro, in patient-derived xenografts, and in patients with relapsed/refractory disease.
Chemotherapy-induced senescent noncancerous cells promote therapy-associated side effects, tumor metastasis, and relapse.
Weaning-induced liver involution establishes a prometastatic liver micro-environment in rodents, which may explain the increased risk for liver metastasis in patients with postpartum breast cancer.
Loss-of-function JAK1/2 mutations induce loss of PD-L1 expression to drive primary resistance to anti–PD-1 therapy.
Expression of the RasGAPs DAB2IP and RASAL2 is concomitantly lost in a subset of aggressive luminal B breast tumors, promoting invasion and metastasis via activation of RAS and NF-κB signaling.
Reduced activity of the APC/C complex induces a mild mitotic delay that reduces segregation errors to allow tumor cells to circumvent the deleterious effects of excessive CIN.